Nektar Left Reassessing After Canceled Melanoma Trials

Nektar Left Reassessing After Canceled Melanoma Trials

Source: 
BioSpace
snippet: 

Shares of Nektar Therapeutics plunged after a disappointing clinical announcement on Monday. This has prompted the cancellation of two trials and left the company scrambling to find solutions.